Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Real-World Study of Dabigatran Etexilate for Thromboprophylaxis in Over 5000 Hip or Knee Replacement Patients: Favourable Safety Profile in Subgroups with Different BMI, Renal Function and Age

Nadia Rosencher, MD, Simon Frostick, MD, Martin Feuring, MD, Eva Kleine, Martina Brueckmann, MD, Andreas Clemens, MD, Charles Marc Samama, MD

Blood (2012) 120 (21): 1160.

https://doi.org/10.1182/blood.V120.21.1160.1160

Published: 2012

Journal Articles

Epidemiological Data On the Incidence of Co-Morbidities and Co-Medications in Patients Undergoing Total Hip or Knee Replacement Surgery: Real-World Study and Phase III Clinical Trials.

Nadia Rosencher, MD, Simon Frostick, MD, Martin Feuring, MD, Eva Kleine, Martina Brueckmann, MD, Andreas Clemens, MD, Charles Marc Samama, MD

Blood (2012) 120 (21): 2269.

https://doi.org/10.1182/blood.V120.21.2269.2269

Published: 2012

Journal Articles

Efficacy and Safety Profile of Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Moderately Renally Impaired Patients after Total Knee or Hip Replacement Surgery.

Ola E Dahl, Andreas A Kurth, Nadia Rosencher, Janet Schnee, Andreas Clemens, Herbert Noack, Bengt I Eriksson

Blood (2008) 112 (11): 981.

https://doi.org/10.1182/blood.V112.11.981.981

Published: 2008

Journal Articles

Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years

Ola E Dahl, Andreas A Kurth, Nadia Rosencher, Janet Schnee, Andreas Clemens, Herbert Noack, Bengt I Eriksson

Blood (2008) 112 (11): 437.

https://doi.org/10.1182/blood.V112.11.437.437

Published: 2008

Journal Articles

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.

Michael R. Lassen, MD, Alexander G.G. Turpie, MD, Nadia Rosencher, MD, Lars C. Borris, MD, Walter Ageno, MD, Jay R. Lieberman, MD, Tiemo J. Bandel, MD, Frank Misselwitz, MD, PhD

Blood (2007) 110 (11): 308.

https://doi.org/10.1182/blood.V110.11.308.308

Published: 2007

Journal Articles

A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).

Bengt I. Eriksson, MD, PhD, Ola E. Dahl, MD,PhD, Cornelis N. van Dijk, MD,PhD, Simon P. Frostick, MA,DM,FRCS, Andreas A. Kurth, MD,PhD, Nadia Rosencher, MD, Janet Schnee, MD, Rohan Hettiarachchi, MD,PhD, Anita V. Christiansen, MSc.Pharm., Stefan Hantel, PhD, Harry R. Büller, MD,PhD

Blood (2006) 108 (11): 573.

https://doi.org/10.1182/blood.V108.11.573.573

Published: 2006

Journal Articles

Sensitivity of a New Global Assay for Protein C (PC) Pathway Abnormalities and Potential Significance of an Abnormal Test Result as a Risk Factor/Marker for Thrombosis Independently of Its Sensitivity for PC Pathway Abnormalities.

Pierre A. Toulon, Nadia Rosencher, Aurélie Guigon, Arnaud Simon

Blood (2005) 106 (11): 2635.

https://doi.org/10.1182/blood.V106.11.2635.2635

Published: 2005

NARROW

Real-World Study of Dabigatran Etexilate for Thromboprophylaxis in Over 5000 Hip or Knee Replacement Patients: Favourable Safety Profile in Subgroups with Different BMI, Renal Function and Age

Epidemiological Data On the Incidence of Co-Morbidities and Co-Medications in Patients Undergoing Total Hip or Knee Replacement Surgery: Real-World Study and Phase III Clinical Trials.

Efficacy and Safety Profile of Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Moderately Renally Impaired Patients after Total Knee or Hip Replacement Surgery.

Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.

A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).

Sensitivity of a New Global Assay for Protein C (PC) Pathway Abnormalities and Potential Significance of an Abnormal Test Result as a Risk Factor/Marker for Thrombosis Independently of Its Sensitivity for PC Pathway Abnormalities.

Email alerts

ASH Publications

American Society of Hematology

Real-World Study of Dabigatran Etexilate for Thromboprophylaxis in Over 5000 Hip or Knee Replacement Patients: Favourable Safety Profile in Subgroups with Different BMI, Renal Function and Age

Epidemiological Data On the Incidence of Co-Morbidities and Co-Medications in Patients Undergoing Total Hip or Knee Replacement Surgery: Real-World Study and Phase III Clinical Trials.

Efficacy and Safety Profile of Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Moderately Renally Impaired Patients after Total Knee or Hip Replacement Surgery.

Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years

Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.

A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).

Sensitivity of a New Global Assay for Protein C (PC) Pathway Abnormalities and Potential Significance of an Abnormal Test Result as a Risk Factor/Marker for Thrombosis Independently of Its Sensitivity for PC Pathway Abnormalities.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only